No Significant Interaction Between Keytruda (Pembrolizumab) and Gabapentin
There is no documented clinically significant interaction between Keytruda (pembrolizumab) and gabapentin, making this combination safe to use without dose adjustments.
Mechanism of Action and Metabolism
Keytruda (Pembrolizumab)
- Pembrolizumab is a monoclonal antibody that targets PD-1 (programmed death-1) receptors
- Unlike small molecule drugs, monoclonal antibodies:
- Are not metabolized through cytochrome P450 enzyme systems
- Are eliminated through proteolytic degradation
- Have minimal potential for drug-drug interactions with medications metabolized by hepatic enzymes
Gabapentin
- Gabapentin binds to voltage-gated calcium channels at the α-δ subunit
- Has a favorable drug interaction profile:
- Not metabolized by the liver
- Excreted unchanged by the kidneys
- Does not induce or inhibit hepatic enzymes
- Has few documented drug interactions 1
Clinical Evidence
The absence of interaction between pembrolizumab and gabapentin is supported by:
- No specific warnings or contraindications regarding this combination in clinical guidelines
- Different metabolic and elimination pathways:
- Pembrolizumab: proteolytic degradation (immune system)
- Gabapentin: renal excretion (unchanged)
Considerations for Clinical Use
Dosing
- No dose adjustments are required when using these medications together
- Standard dosing can be maintained for both medications:
- Gabapentin: Starting at 100-300 mg at bedtime or 100-300 mg three times daily, titrated as needed 1
- Pembrolizumab: Standard oncology protocols based on indication
Monitoring
While no specific interaction exists, monitor for:
- Expected side effects of each medication individually
- Gabapentin side effects: dizziness, sedation, peripheral edema
- Pembrolizumab side effects: fatigue, pruritus, diarrhea, rash, immune-mediated adverse events 1
Special Populations
Renal Impairment
- Gabapentin requires dose adjustment in renal impairment as it is eliminated by the kidneys 1
- Pembrolizumab does not require dose adjustment for renal impairment
Hepatic Impairment
- Neither medication requires significant dose adjustment for mild hepatic impairment
- Pembrolizumab has been studied in patients with various cancer types and comorbidities without specific hepatic dose adjustments
Conclusion
The combination of pembrolizumab and gabapentin can be safely administered without concerns for pharmacokinetic or pharmacodynamic interactions. This is particularly beneficial for cancer patients who may require gabapentin for neuropathic pain management, which is common in cancer treatment.